Formulation and evaluation of orally disintegrating clopidogrel tablets by Mahrous, Gamal Mohamed et al.
*Correspondence: Gamal Mohamed Mahrous. Department of Pharmaceutics. 
College of Pharmacy. King Saud University. Riyadh 11454. P.O. Box 2457. 
Kingdom of Saudi Arabia. E-mail: gmmahroos@yahoo.com
A
rt
ic
leBrazilian Journal of 
Pharmaceutical Sciences
vol. 52, n. 2, apr./jun., 2016
http://dx.doi.org/10.1590/S1984-82502016000200009
Formulation and evaluation of orally disintegrating clopidogrel 
tablets
Gamal Mohamed Mahrous1,*, Mohamed Gabr Kassem2, Mohamed Abbas Ibrahim1,3, 
Sayed Hassan Auda1,3
1Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Kingdom of Saudi Arabia, 2Department 
of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Kingdom of Saudi Arabia, 1Department of 
Pharmaceutics and Industrial Pharmacy, College of Pharmacy, Al Azhar University, Assiut, Egypt
Recent advances in drug delivery systems have aimed to achieve better patient compliance. One of these 
advances is the formulation of orally disintegrating tablets (ODTs) that dissolve instantaneously, releasing 
drugs within a few seconds without the need of water. The main objective of this paper was to prepare 
and develop ODTs of clopidogrel. The ODTs were prepared by direct compression. The effect of three 
superdisintegrants, namely crospovidone, croscarmellose sodium, and sodium starch glycolate, using 
three different disintegration times on the dissolution rate was investigated. The prepared tablets were 
evaluated for hardness, friability, disintegration time and in vitro drug release. Furthermore, the interaction 
of clopidogrel with the formulation excipients was studied using differential scanning calorimetry (DSC). 
DSC studies revealed that there were no interactions between the drug and the excipients used. All tablets 
had hardness values in the range 4.0–5.2 kp and friability lower than 1%. The weight and drug content 
uniformity of all formulations was within official limits according to BP. In vitro drug release studies of 
the ODTs showed that more than 90% of the drug was released within ten minutes. A palatability test 
in human volunteers showed acceptable taste and mouth feel. Thus, the obtained results conclusively 
demonstrated successful rapid disintegration of the formulated tablets and acceptable palatability.
Uniterms: Clopidogrel/orally disintegrating tablets. Superdisintegrants. Orally disintegrating tablets/
formulation. Orally disintegrating tablets/evaluation.
Recentes avanços em sistemas de liberação de fármacos novos visam à obtenção de melhor adesão 
do paciente. Um destes avanços é a formulação de comprimidos de desintegração oral (ODTs), que 
se dissolvem instantaneamente, liberando o fármaco, em alguns segundos, sem a necessidade de 
água. O principal objetivo deste trabalho foi preparar e desenvolver ODTs de clopidogrel. Os ODTs 
foram preparados pelo método de compressão direta. Estudou-se o efeito de várias concentrações de 
diferentes agentes de desintegração, tais como super-crospovidona, croscarmelose de sódio, glicolato 
de amido de sódio no tempo de desintegração e velocidade de dissolução. Os comprimidos preparados 
foram avaliados quanto à dureza, à friabilidade, ao tempo de desintegração e à liberação do fármaco in 
vitro. Além disso, estudou-se a interação de clopidogrel com os excipientes de formulação, utilizando 
calorimetria de varredura diferencial (DSC). Estudos de DSC revelaram não haver interação entre o 
fármaco e os excipientes utilizados. Todos os comprimidos possuíam dureza na faixa de 4,0-5,2 kp e a 
friabilidade inferior a 1%. A variação de peso e o teor de fármaco de todas as formulações mostraram-se 
dentro do limite oficial, de acordo com a BP. O estudo de liberação do fármaco in vitro de comprimidos 
ODTs mostrou que mais de 90% do fármaco foram liberados em10 minutos. O teste de palatabilidade 
em voluntários humanos mostrou sabor e sensação na boca aceitáveis. Assim, os resultados obtidos 
demonstraram, conclusivamente, a rápida e bem-sucedida desintegração dos comprimidos formulados 
e a palatabilidade aceitável.
Unitermos: Clopidogrel/comprimidos de desintegração oral. Superdesintegrantes. Comprimidos/de 
desintegração oral/formulação. Comprimidos/de desintegração oral/avaliação.
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INTRODUCTION
Formulations administered via the oral route 
represent 50–60% of the total pharmaceutical dosage forms 
in the market (Bandelin, 1989). The oral administration 
route is considered to be the most widely accepted route 
because of its convenience, ease of administration, 
avoidance of pain and patient compliance (Bandelin, 
1989). However, many paediatric and geriatric patients are 
unwilling to take solid preparations due to a fear of choking 
or because of difficulty in swallowing (dysphagia). Also, 
the swallowing of oral dosage forms requires water, which 
might be not available in some cases (Kuccherkar, Badhan, 
Mahajan, 2003; Suresh et al., 2008). For these reasons, 
tablets that can rapidly dissolve or disintegrate in the oral 
cavity have attracted a great deal of attention (Porter, 2001; 
Mostafa, Ibrahim, Sakr, 2013). These tablets are called 
fast dissolving tablets, orally disintegrating tablets (ODTs) 
or mouth-dissolving tablets. Fast dissolving tablets are 
those which, when put onto the tongue, disintegrate 
instantaneously releasing the drug, which dissolves 
or disperses in the saliva (Venkateswara, Nyshadham, 
Joseph, 2003). Orally disintegrating tablets are defined 
as solid oral preparations that disintegrate rapidly in the 
oral cavity with an in vitro disintegration time of less than 
30 seconds, according to FDA guidelines (DHHS, 2008).
The use of superdisintegrants is essential in 
development of orally disintegrating tablets. Examples 
of these are: cross-linked carboxymethyl cellulose 
(croscarmellose®), sodium starch glycolate (primogel®, 
explode®) and crospovidone (polyplasdone®). These 
superdisintegrants provide instantaneous disintegration 
of the tablet when it is placed on the tongue. The 
bioavailability of some drugs may be increased due to 
absorption of some of the drug in the oral cavity, and also 
due to pregastric absorption of saliva containing dispersed 
drug that passes down into the stomach. Moreover, the 
amount of drug that is subjected to first pass metabolism 
is reduced compared with conventional tablets (Biradar, 
Bhagavati, Kuppasad, 2006).
Clopidogrel hydrogen sulphate (named hereafter 
clopidogrel) was discovered by Sanofi. It is now 
marketed by Sanofi–Synthelabo worldwide under the 
brand name PLAVIX®. Clopidogrel is an antiplatelet 
agent, which selectively inhibits the binding of adenosine 
diphosphate (ADP) to its platelet receptor and blocks 
the subsequent GPIIb/IIIa complex, thereby inhibiting 
platelet aggregation (Jarvis, Simpson, 2000). The clinical 
benefits of clopidogrel have been demonstrated and 
it is used worldwide for the long-term prevention of 
atherothrombotic events such as myocardial infarction, 
stroke, peripheral arterial disease and acute coronary 
syndrome (Jarvis, Simpson, 2000). 
In a previous study, Sahitya et al. (2014) formulated 
a solid dispersion of clopidogrel into fast dissolving tablets. 
However, such formulations have reduced palatability due 
to the rapid dissolution in the mouth. 
The aim of the present work was to prepare fast 
disintegrating clopidogrel tablets by direct compression 
and to study the effect of the type and concentration of 
the superdisintegrant used on the physical properties of 
the prepared tablets, as well as on drug dissolution and 
disintegration. The direct compression technique was 
selected rather than wet granulation because the porous 
nature of tablets prepared by direct compression results 
in faster disintegration.
MATERIAL AND METHODS
Clopidogrel hydrogen sulphate (CL) was kindly 
donated by Tabuk Pharmaceutical manuf. Co, Tabuk, 
Saudi Arabia. Microcrystalline cellulose (Avicel® PH101) 
was purchased from Serva Feinbiochemica (Heidelberg, 
Germany). Spray dried mannitol (MannogemTM EZ), used 
as a filler for the orally disintegrating tablets, was kindly 
supplied by SPI, Grand Haven, USA. Croscarmellose 
sodium (CCS), sodium starch glycolate (SSG) and 
crospovidone (CPV) were kindly supplied by Riyadh 
Pharma, Riyadh, KSA. Magnesium stearate was purchased 
from Riedel-de Haën, Seelze, Germany. Potassium 
dihydrogen orthophosphate and Sodium hydroxide were 
purchased from Merck, Darmstadt, Germany.
METHODOLOGY
Differential scanning calorimetry (DSC)
The thermal behaviour of CL alone and in physical 
mixtures with tablet excipients was studied using DSC. 
Samples (3-5 mg) were weighed and hermetically sealed in 
aluminium pans and heated at a constant rate of 10 °C/min, 
in a temperature range from 25 °C to 250 °C. Thermograms 
of the samples were obtained using differential scanning 
calorimetry (DSC-60, Shimadzu, Japan). Thermal analysis 
data were recorded using a TA 50I PC system with 
Shimadzu software programs. An indium standard was 
used to calibrate the DSC temperature and enthalpy scale. 
N2 was used as the purging gas at a rate of 30 mL/min. 
Fourier transform infrared spectroscopy (FTIR)
The FTIR spectra of TNX, KL and their binary 
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systems were recorded using a Perkin Elmer FTIR 
spectrophotometer (Spectrum BX). Samples were mixed 
with potassium bromide (spectroscopic grade) and 
compressed into disks using a hydraulic press before 
scanning from 4000 to 600 cm-1. The data were analysed 
using Perkin Elmer software (Spectrum V5.3.1).
Pre-compression evaluation
The flow properties of the powder mixtures of 
different compositions were evaluated in terms of their 
bulk density, tapped density, angle of repose, Carr’s index 
and Hausner ratio.
Preparation of clopidogrel hydrogen sulphate (CL) 
tablets by direct compression
The calculated amounts of CL, superdisintegrant and 
microcrystalline cellulose (MCC 101) shown in Table 1 
were accurately weighed and blended in a Turbula mixer 
(Erweka, S2Y, Heusenstamm, Germany) for five minutes. 
Thereafter, the formula weight of mannitol was mixed with 
the MCC-superdisintegrant mixture for 10 min. Finally, 
the correct amount of magnesium stearate was mixed with 
the powder blend for a further 2 minutes. After mixing, 
the powder blend was compressed into shallow concave 
tablets weighing 300 mg using a Korsh single punch 
machine with 9 mm punches (Erweka, EKO, Germany).
Evaluation of the prepared tablets
Weight variation
Twenty tablets from each batch were individually 
weighed (Analytical balance, Shimadzu, EB-3200D, 
Tyoto, Japan) and the average weight ± SD was calculated.
Hardness
The tablet crushing strength (hardness) was 
investigated using a hardness tester (Pharma test GmbH, 
Hainburg, Germany) for samples of 10 compressed tablets 
for each tablet formula. The average values of weight ± 
SD were recorded.
Friability
The percentage loss in weight of tablets (friability) 
was calculated based on the pharmacopeial test (USP, 
2011, 34-NF29). Twenty accurately weighed tablets 
(W1) were placed in the friability tester (Erweka, TA3R, 
Heusenstamm, Germany), and allowed to rotate for 4 min 
at 25 rpm. After removal of fines, tablets were reweighed 
(W2), and the percentage weight loss was calculated from 
the following equation:
 100 × (W1 − W2)/W1.
Clopidogrel content
An orally disintegrating clopedogril tablet weighing 
300 mg and equivalent to 75 mg clopedogril was 
accurately weighed, finely powdered, and transferred 
into a volumetric flask. About 60 mL of 0.1 N HCl 
was added and the flask was sonicated for 10 min, 
then shaken mechanically for 30 min and the volume 
made up to 100 mL with the same solvent, followed by 
sonication and filtration. The drug content was determined 
spectrophotometrically at 240 nm (Ashraf Z. et al.; 2015). 
The test was repeated for ten individual tablets and the 
TABLE I - Composition of various clopidogrel hydrogen sulphate (CL) orally disintegrating tablet formulations
Formula
Ingredients (%w/w)
CL MCC Mannitol CCS SSG CPV Aspartame & mag-stearate
F1 25 36 36 - - - 2,1
F2 25 35.0 35.0 2.0 - - 2,1
F3 25 33.5 33.5 5.0 - - 2,1
F4 25 31.0 31.0 10.0 - - 2,1
F5 25 35.0 35.0 - 2.0 - 2,1
F6 25 33.5 33.5 - 5.0 - 2,1
F7 25 31.0 31.0 - 10.0 - 2,1
F8 25 35.0 35.0 - - 2.0 2,1
F9 25 33.5 33.5 - - 5.0 2,1
F10 25 31.0 31.0 - - 10.0 2,1
The total tablet weight was 300 mg. CL: Clopidogrel, MCC: Microcrystalline cellulose (Avicel PH 101), CCS: Crosscarmelose 
sodium, SSG: Sodium starch glycolate, CPV: Crospovidone
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average drug content ± SD was presented.
In vitro disintegration
The disintegration times of the manufactured 
tablets were evaluated in vitro using a USP disintegration 
apparatus operated at 37 °C ± 2 °C, using phosphate buffer 
(pH 6.8) as the disintegration medium (USP 34-NF29; 
2011). One tablet was introduced into each of the six tubes 
of the basket (Electrolab, ED-21, Pumbai, India). The time 
required for complete tablet disintegration was recorded 
and the mean ± SD of six tablets was calculated.
In vitro dissolution studies
The release measurements were performed using a 
USP dissolution apparatus 2 (Caleva Ltd., Model 85T), 
using the paddle method at 50 rpm. Each flask contained 
500 mL 0.1N HCl, adjusted to pH 2.0 or phosphate buffer 
at pH 6.8 maintained at 37 ± 0.5 °C. At predetermined time 
points (5, 10, 15, 20 and 30 minutes), a 5 mL sample was 
withdrawn and replaced with fresh dissolution medium. 
The absorbances of the withdrawn samples were measured 
spectrophotometrically at 240 nm and the percentage of 
drug dissolved was calculated. The test was performed on 
CL containing tablets in triplicate.
In vivo disintegration and palatability studies
Ten healthy male volunteers (18-55 years old) 
were administered the selected formula (F9). The tested 
formula was allowed to disintegrate in the mouth and 
then disgorged. The taste, its extent, the after taste and 
other effects such as numbness (if any) were recorded as 
displayed in Table II. The study was approved by the King 
Saud University Ethics committee, Riyadh, Saudi Arabia.
RESULTS AND DISCUSSION
Differential scanning calorimetry (DSC) and 
Fourier transform infrared spectroscopy (FTIR)
Differential scanning calorimetry (DSC) was used 
to evaluate the melting point, crystallinity, decomposition 
and drug-excipient interaction by studying the thermal 
behaviour of the preparations (El Badry, 2008). DSC scans 
were performed on the drug, the tested excipients and 
their corresponding physical mixtures. The DSC scan of 
untreated clopidogrel showed a characteristic endothermic 
peak at 184 °C (Figure 1), which corresponds to its melting 
point. None of the tested additives had characteristic peaks 
in the temperature range studied, except for mannitol, 
which showed a sharp peak at 168 oC (Figure 2). For the 
corresponding physical mixtures of the drug with all of the 
additives except mannitol, the characteristic endothermic 
peak of the drug was seen in its melting range (184±3 
oC), but with lower intensity (Figure 2). This indicates 
that there is no interaction between clopidogrel and 
these excipients. Upon scanning the DSC thermogram 
of the drug-mannitol physical mixture, the drug fusion 
peak appeared at about 154 oC suggesting an interaction 
between the drug and mannitol.
IR spectra (Figure 3) of clopidogrel, mannitol and 
their physical mixture were recorded in order to determine 
whether there was a chemical interaction between 
them. The IR spectrum of clopidogrel is characterised 
by principal absorption peaks at 3107.16 cm-1 (C-H 
aromatic), 1752 cm-1 (C=O stretching), and 1178 cm-1 
(C-O stretching) (Shailendra, Soukarya, Upender, 2011). 
TABLE II - Palatability evaluation
Effect
Scale After Effects
1 2 3 4 +
Taste Bad Acceptable Good Excellent After taste
Mouth feel Gritty Acceptable Good Excellent Numbness
FIGURE 1 - Differential scanning calorimetric (DSC) 
thermograms of the drug and the tested excipients: (A) 
Clopidogrel; (B) Microcrystalline cellulose; (C) Crospovidone; 
(D) Starch sodium glycolate; (E) Croscarmellose; (F) Mannitol.
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All of the principal absorption beaks of clopidogrel 
appeared in the physical mixture at the same positions. 
No additional peaks were observed in case of the physical 
mixture. These results indicate that there is no chemical 
interaction between clopidogrel and mannitol. 
Pre-compression evaluation
The blends of the drug and various tablet excipients 
were evaluated for their micromeritic characteristics 
as shown in Table III. The calculated bulk density was 
between 0.39-0.44 g/cc and the tapped density was 
between 0.398±0.007 and 0.43–0.50 gm/cc for all tested 
powder blends. The angle of repose and Carrs indices 
were found to be in the ranges 31.0-34.5 and 10-12.5%, 
respectively. The Hausner ratio was found to be below 
1.15. All of the formulations showed the good blend 
properties required for direct compression and hence 
tablets were prepared using direct compression.
Tablet Evaluation
The manufactured ODTs containing 75 mg CL 
were successfully prepared using the direct compression 
method. The manufactured ODTs were evaluated for their 
weight uniformity, hardness, friability, and CL content as 
well as for their disintegration time, and the obtained data 
are summarised in Table 4. The measured tablet weights 
ranged from 0.295-0.304 g and the average tablet hardness 
was found to be 4.2-5.2 kp. Moreover, the tablets exhibited 
FIGURE 2 - Differential scanning calorimetric (DSC) 
thermograms of clopidogrel and its physical mixtures with the 
tested excipients: (A) Clopidogrel; (B) drug:microcrystalline 
cellulose; (C) drug:crospovidone; (D) drug:starch sodium 
glycolate; (E) drug:croscarmellose; (F) drug:mannitol.
FIGURE 3 - FTIR spectra of: A) clopidogrel, B) mannitol, C) 
clopidogrel:mannitol physical mixture.
TABLE III - The precompression parameters of the powder blends
Formulation code Angle of repose(Ø)
Bulk density 
(g/cc)
Tapped density 
(g/cc)
Carr’s index 
(%) Hausner Ratio
F1 32.4 ±0.48 0.44 ±0.005 0.50±0.006 12.28 1.14
F2 33.3 ±0.58 0.42±0.004 0.46±0.004 10 1.1
F3 34 ±0.68 0.41±0.005 0.46±0.005 11.48 1.13
F4 34.5 ±0.66 0.4±0.004 0.45±0.004 11.29 1.13
F5 33 ±0.61 0.4±0.003 0.45±0.004 11.29 1.13
F6 33.5 ±0.60 0.39±0.003 0.43±0.005 9.57 1.04
F7 33.6 ±0.58 0.39±0.004 0.45±0.006 12.5 1.14
F8 30.4 ±0.35 0.42±0.003 0.46±0.003 10 1.13
F9 31 ±0.40 0.41±0.004 0.46±0.004 11.48 1.13
F10 31.8 ±0.49 0.39±0.004 0.43±0.004 9.4 1.1
Mean of three experiments (mean ± SD).
G. M. Mahrous, M. G. Kassem, M. A. Ibrahim, S. H. Auda314
acceptable friability that was less than 1% in all ODT 
formulations.
Tablet Disintegration
The impact of the use of different disintegrants on 
the time required for disintegration of the ODTs containing 
75 mg CL is displayed in Table IV.
It  is  clearly evident from the data that the 
superdisintegrants used caused a pronounced decrease 
in the disintegration time of the prepared ODTs, 
especially CCS and CPV. Tablets formulated without 
superdisintegrants exhibited a disintegration time of about 
236 seconds.
Using CCS and CPV as superdisintegrants, when the 
concentration of the superdisintegrant was increased from 
2% to 5%, enhanced tablet disintegration was observed. 
Increasing the concentration of CCS or CPV from 5% to 
10% in the tablets did not show any further significant 
increase in the disintegration rate. Also, increasing 
the concentration of SSG from 2% to 5% resulted in a 
reduction of the disintegration time from 58 seconds to 
53 seconds, while increasing the concentration of the 
superdisintegrant from 5% to 10% did not show any 
further significant change. It can be concluded that the 
optimum concentration of superdisintegrant is 5%, which 
gave rapid disintegration of CL tablets. These results are 
in agreement with those found by Ferrero et al., who 
studied the disintegration efficiency of croscarmellose 
sodium and reported that at high concentrations (> 8%), 
the disintegration time was found to be longer (Ferrero et 
al., 1997). Moreover, Jagdale et al. (2010) mentioned that 
CCS gave a short disintegration time at low concentrations 
with a sudden rise when the concentration was increased 
from 4% to 6%. The authors interpreted these results 
on the basis of that the fibrous nature of CCS at low 
concentrations is responsible for its disintegrating action, 
which results from the wicking of water into tablet 
matrices. The fibrous nature of CCS is more pronounced at 
lower concentrations and smoothens gradually with time. 
There is a probability that wicking and swelling occur 
simultaneously, thus, at high concentrations smoothening 
of the particles and decrease in the width of the pores may 
prevail (Jagdale et al., 2010).
The tablet formulation containing 5% CPV (F9) 
could be considered as optimum as it had shortest 
disintegration time. These results are in accordance with 
an earlier study by Balasubramaniam et al. (2008), where 
the disintegration time of clopidogrel tablets containing 
Polyplasdone XL showed the fastest release in compendial 
medium (pH 2.0), compared with SSG and croscarmellose 
sodium. The authors explained their results on the basis that 
of the commonly used superdisintegrants, crospovidone 
is nonionic, while SSG and croscarmellose sodium are 
anionic. It has been proposed that any weakly basic 
(cationic) drug, when present in an environment where the 
pH is >2 and near or below the pKa of the cationic drug, 
should be expected to interact with ionised polymers like 
croscarmellose sodium and SSG (Balasubramaniam et 
al., 2008).
In vitro dissolution
The in vitro dissolution profiles of CL from the 
prepared orally disintegrating tablets in the compendial 
medium (pH 2.0) are displayed in Figures 4-6. The drug 
exhibited only 5 % dissolution from the tablet formula 
without superdisintegrant after the first 5 minutes, and 
TABLE IV - Physical properties of orally disintegrating clopidogrel tablets (Mean ± SD)
Weight 
(mg)
Disintegration 
time* (sec.)
CL Content 
(%)+/-SD
Hardness 
(Kp)
Friability  
(%)
F1 299±0.39 236±5.0 101.30 ± 0.51 4.0±0.50 0.86±0.10
F2 301±0.54 29± 0.87 99.50 ± 0.42 4.8±0.28 0.81±0.15
F3 300±0.72 24±0.58 98.80 ± 0.50 4.8±0.16 0.87±0.14
F4 304±0.63 24±0.60 100.10 ± 0.66 4.8±0.19 0.74±0.24
F5 298±0.61 58±1.0 101.00± 0.72 5.1±0.21 0.79±0.16
F6 302±0.37 53±1.00 98.77 ± 0.53 5.1±0.23 0.70±0.31
F7 299±0.49 53±1.00 101.30 ± 0.60 4.6±0.34 0.75±0.21
F8 301±0.73 22±1.53 102.10 ± 0.80 4.6±0.28 0.76±0.20
F9 299±0.68 17±0.58 103.20± 0.63 5.2±0.49 0.79±0.21
F10 302±0.38 17±1.00 101.30 ± 0.66 4.2±0.30 0.88±0.11
* Experiments were carried out in phosphate buffer (pH 6.8).
Formulation and evaluation of orally disintegrating clopidogrel tablets 315
completed dissolution after 20 minutes. This observation 
was in agreement with the higher disintegration times 
expected with such formulas. However, the presence of 
superdisintegrants in the tablet formulations caused an 
enhanced initial dissolution rate of CL, especially at the 
5% superdisintegrant level. For example, more than 95% 
of the loaded CL dissolved from ODTs containing a 5 % 
concentration of CCS, CPV or SSG after 5 minutes.
The dissolution CL from ODT formulations F3, 
F6 and F9 (containing 5% each of CCS, SSG, and CPV, 
respectively) was studied in two different dissolution 
media, at pH 2.0 and pH 6.8 and the results are displayed 
in Figure 7.
Clopidogrel exhibited very slow dissolution rates 
from the formulas at the higher pH value (no more than 
30% was released after 30 minutes), while complete drug 
dissolution from both formulas was observed after 15 
minutes at the lower pH (pH 2.0). This phenomenon is due 
to the lower solubility of CL at higher pH values because 
of its basic nature (Sahitya et al., 2014). This might be 
advantageous during the formulation of CL ODTs, since 
the manufactured ODTs formulations containing the drug 
exhibited rapid disintegration at the higher pH value (pH 
6.8), which simulates saliva fluid, while the drug dissolves 
slowly, which may mask its undesirable taste.
Evaluation of palatability
The results of palatability test were illustrated in 
Tables V and VI. Half of the volunteers reported that 
the palatability was acceptable while the other half 
reported good palatability. Only two volunteers out of 
ten complained of a mild bitter after taste. In evaluation 
of mouth feel, eight of the volunteers reported that it was 
acceptable while the other two exhibited taste responses 
with no complaints of numbness. These results indicate 
the acceptable palatability of the formulated tablets. The 
mean in vivo disintegration time for the ten volunteers was 
FIGURE 6 - Effect of CPV concentration on the percentage of 
Clopidogrel dissolved in an acidic medium, pH 2.0.
FIGURE 5 - Effect of SSG concentration on the percentage of 
Clopidogrel dissolved in an acidic medium, pH 2.0.
FIGURE 4 - Effect of CCS concentration on the percentage of 
Clopidogrel dissolved in an acidic medium, pH 2.0.
FIGURE 7 - Effect of the pH of the dissolution medium on the 
percentage of Clopidogrel dissolved.
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about ten seconds, which is in accordance with the in vitro 
disintegration time for F9.
CONCLUSION
In conclusion, ODTs of CL were developed that had 
sufficient mechanical integrity, and uniformity of content 
with acceptable palatability to allow easy administration 
to patients of any age group. The ODTs were prepared by 
direct compression. All tablets had hardness in the range 
4.2–5.2 kp and friability less than 1%. Weight variation 
and drug content of all formulations were within official 
limits. In vitro disintegration tests and in vitro drug release 
studies of ODTs tablets showed a fast disintegration within 
seconds at pH 6.8 and more than 90% of the drug was 
released within 5 minutes in acidic medium.
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